10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs

5. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Amicus jumped to a new 52-week high on Friday, as investors took heart from an investment firm’s optimistic coverage and bullish rating for its stock.

At intra-day trading, the stock climbed to its highest price of $10.85 before trimming a few cents to finish the session just up by 6.57 percent at $10.55 apiece.

In a market report, Zacks Research issued a “strong buy” recommendation for Amicus Therapeutics, Inc. (NASDAQ:FOLD), saying that there could be plenty of upside left in the stock, with the consensus price target of $15.90 implying a potential upside of 50.7 percent from its latest closing price.

Additionally, Zacks highlighted several analysts’ higher EPS targets for the stock, boosted by optimism about Amicus Therapeutics, Inc.’s (NASDAQ:FOLD) ability to report better-than-expected earnings.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a global biotechnology company focused on discovering, developing, and delivering novel, high-quality medicines for people living with rare diseases.

In the third quarter of the year, it swung to a net income attributable to shareholders of $17.3 million from a $6.7 million net loss in the same period last year.

Net product sales jumped by 20 percent to $169 million from $141 million year-on-year, on the back of strong revenues from Galafold and Pombiliti + Opfolda.

Galafold alone recorded $138 million in sales, higher by 15 percent than the $120.38 million in the same period last year, while Pombiliti + Opfolda sales surged by 45 percent to $30.7 million from $21 million.